MICROFLUIDICS INNOVATION CENTER

Their core work

Microfluidics Innovation Center is a Paris-based SME that designs and fabricates microfluidic chips and bioprinting systems for research and biomedical applications. They provide specialized microfabrication services to EU research consortia working on organ-on-chip models, nanomedicine delivery, tissue engineering, and chemical safety testing. Their core value is translating microfluidics and laser fabrication expertise into functional lab-on-chip devices that enable other teams to run complex biological experiments — from tumor migration studies to placental drug safety models.

What they specialise in

How they've shifted over time

All six projects started between 2020 and 2021, so the evolution window is narrow but still visible through topic shifts. Early projects focused on physical fabrication — laser microfabrication of quantum emitters (LasIonDef), organ-on-chip construction (Tumor-LN-oC), and CO2 valorisation chemistry (BIOALL). More recent projects pivot strongly toward biomedical and regulatory applications: chemical mixture toxicity on cardiac tissue (ALTERNATIVE), drug safety during pregnancy via placenta-on-chip (LIFESAVER), and nanomedicine imaging tools (Micro4Nano). The trajectory is clear — from fabrication as a physics/engineering service toward fabrication as an enabler of biomedical safety and regulatory science.

Moving from general-purpose microfabrication toward specialized organ-on-chip platforms for toxicology, drug safety, and regulatory testing — a high-growth market driven by EU demand for animal-testing alternatives.

How they like to work

Exclusively a participant across all six projects — they never lead consortia but consistently contribute specialist fabrication capabilities. With 62 unique partners across 27 countries, they spread their expertise widely rather than deepening ties with a fixed group, which is typical of a technology service provider that different teams bring in for their specific manufacturing skills. Their mix of MSCA (training/mobility) and RIA (research) projects suggests they also host visiting researchers and train others in microfluidic techniques.

Remarkably broad network for a small company: 62 unique consortium partners across 27 countries, indicating they are a sought-after specialist that diverse European teams recruit for microfluidic fabrication. No single geographic cluster — their reach is genuinely pan-European and beyond.

What sets them apart

Their distinctive value is sitting at the intersection of precision microfabrication (lasers, lithography) and biological tissue modeling (bioprinting, organ-on-chip) — a rare combination in a single SME. While many labs can design a chip or culture cells, few can do both from fabrication to functional biological platform. For consortium builders, they offer a turnkey partner who can take a biological question (how does a tumor migrate? is this drug safe for a fetus?) and deliver a working microfluidic device to test it.

Highlights from their portfolio

• LasIonDef
  Their largest project (EUR 549K, 60% of total funding) — an MSCA training network on quantum emitter fabrication, showing deep laser microfabrication roots before their biomedical pivot.
• Tumor-LN-oC
  Combines their bioprinting and microfluidics expertise to build tumor-and-lymph-node-on-chip — directly relevant to the booming organ-on-chip market for cancer research.
• LIFESAVER
  Addresses a critical gap in drug safety testing during pregnancy using placenta-on-chip models — high societal impact and regulatory relevance.